Recorded as renamed to Kyowa Kirin Co., Ltd. (2019)
49 patents currently held
53 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2026. from the record
Of the 53 now held by other companies, 43 name Kyowa Kirin Co. Ltd. as their current owner, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
29
Ending by 2030
Nov 2026
Next term end
37
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Aug 2027 · Medium confidence
Also notable
Ends Aug 2029 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends May 2027 · High confidence
ANTI-TIM-3 Antibody
US 8,552,156
The most cited patent in this portfolio, cited by 133 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2031.
Method for Treatment of Blood Tumor Using ANTI-TIM-3 Antibody
US 8,647,623
Cited by 45 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Antagonistic Human Light-Specific Human Monoclonal Antibodies
US 8,974,787
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Stabilized Human IGG2 and IGG3 Antibodies
US 8,716,451
Cited by 78 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Pharmaceutical Agent Comprising ANTI-BMP9 Antibody as Active Ingredient for Treatment of Anemia Such as Renal Anemia and Cancer Anemia
US 8,969,040
Cited by 48 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Recombinant Antibody Composition
US 7,923,538
Cited by 65 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Novel Antibody and Antibody Fragment Introduced New Modification Sites
US 10,233,246
Granted 2019. Computed term ends 2032.
Thiazole Derivatives
US 7,718,808
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Formerly held, still cited
Notable
Ends Nov 2035 · Medium confidence
Granted 2022. Computed term ends 2035.
now held by Novo Nordisk A/S
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Therapeutic Method and Medicament for HTLV-1 Associated Myelopathy (US 10,294,302) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 1 fee due Feb 11, 2027The maintenance fee for Method for Treatment of Blood Tumor Using ANTI-TIM-3 Antibody (US 9,103,832) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 1 fee due Jun 8, 2027The maintenance fee for ANTI-FOLR1 Antibody (US 9,207,238) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Agonistic ANTI-CD40 IGG2 Antibodies Having Amino Acid Mutations Introduced Therein (US 9,234,044) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
- 5 terms have ended since Aug 23, 2026
- Oct 21 US 8,865,731 Inhibitor of Analgesic Tolerance · lapsed on the fee record
- Oct 16 US 10,100,120 Antibody Which Specifically Binds to Human CRTH2 · lapsed on the fee record
- Oct 14 US 9,085,807 Strain-Independent Amplification of Pathogens and Vaccines Thereto · term ended
- Oct 9 US 10,093,719 Methods for Producing Stabilized Human IGG2 and IGG3 Antibodies · lapsed on the fee record
- Sep 20 US 7,605,272 IGF-1R Inhibitor · term ended
What they patent
The largest of its 37 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,969,810 | Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same In force · Medium confidence | In force | Medium confidence | |
| US 8,192,736 | Remedy for Endometriosis In force · High confidence | In force | High confidence | |
| US 9,475,878 | Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same In force · Medium confidence | In force | Medium confidence | |
| US 7,718,808 | Thiazole Derivatives In force · High confidence | In force | High confidence | |
| US 8,974,787 | Antagonistic Human Light-Specific Human Monoclonal Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 7,923,538 | Recombinant Antibody Composition In force · High confidence | In force | High confidence | |
| US 8,318,201 | Method of Stabilizing Diarylvinylene Compound In force · High confidence | In force | High confidence | |
| US 9,771,419 | Antagonistic Human Light-Specific Human Monoclonal Antibodies In force · Low confidence | In force | Low confidence | |
| US 8,283,450 | Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same In force · High confidence | In force | High confidence | |
| US 7,928,098 | Therapeutic And/Or Preventive Agents for a Sleep Disorder In force · High confidence | In force | High confidence |
Also on record, not counted in the 49: 53 patents in force now held by others · 253 patents ended · 1 application pending · 198 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.